8-KEarnings & Results

DEXCOM INC 8-K Report, Financial Results (Jan 10, 2012)

Filed January 10, 2012For Securities:DXCM

Summary

DexCom, Inc. (DXCM) announced preliminary, unaudited product revenues for the fourth quarter of 2011, reaching approximately $20.8 million. This represents a significant increase of approximately 25% sequentially from the third quarter of 2011 and a robust 53% year-over-year growth compared to the fourth quarter of 2010. For the full fiscal year 2011, DexCom reported estimated product revenues of approximately $65.8 million, marking a substantial 64% increase from the previous year. The company also provided its initial product revenue guidance for fiscal year 2012, projecting a range of $85.0 million to $92.0 million. These results and projections were shared in conjunction with remarks made by the CEO at the J.P. Morgan 30th Annual Healthcare Conference. While these figures indicate strong top-line growth and positive future outlook, investors should note that these are preliminary estimates and are subject to finalization in DexCom's upcoming Form 10-K filing. The report also includes forward-looking statements and a detailed discussion of the associated risks and uncertainties.

Key Highlights

  • 1Q4 2011 preliminary product revenue estimated at $20.8 million, a 25% sequential increase.
  • 2Q4 2011 product revenue increased by 53% compared to Q4 2010.
  • 3Full year 2011 product revenue estimated at $65.8 million, a 64% increase from 2010.
  • 4Fiscal year 2012 product revenue guidance issued between $85.0 million and $92.0 million.
  • 5Information presented at the J.P. Morgan 30th Annual Healthcare Conference.
  • 6Report includes standard forward-looking statements and risk factor disclosures.

Frequently Asked Questions

DexCom reported preliminary, unaudited product revenues of approximately $20.8 million for the fourth quarter of 2011. This represents a 25% increase from the prior quarter and a 53% increase from the fourth quarter of 2010.

For fiscal year 2011, DexCom's estimated product revenue was approximately $65.8 million, showing a significant 64% growth compared to fiscal year 2010.

The company provided initial product revenue guidance for fiscal year 2012, projecting a range of $85.0 million to $92.0 million.

No, the Q4 2011 financial results are estimated and unaudited. They are subject to finalization in connection with the preparation of DexCom's Annual Report on Form 10-K for the period ending December 31, 2011.